BioLineRx (BLRX) Operating Expenses (2011 - 2026)

BioLineRx's Operating Expenses history runs 14 years deep, the most recent figure standing at -$3.5 million for Q4 2025.

• In Q4 2025, Operating Expenses rose 6.37% year-over-year to -$3.5 million; the TTM figure through Dec 2025 stood at -$11.2 million (up 27.36% YoY), while the FY2025 annual figure was -$11.2 million, up 27.36% from the prior year.
• Operating Expenses for Q4 2025 stood at -$3.5 million, down from -$2.6 million in the prior quarter.
• The five-year high for Operating Expenses was $4.3 million in Q2 2022, with the low at -$6.3 million in Q4 2021.
• The 5-year median for Operating Expenses is -$4.1 million (2023), against an average of -$3.5 million.
• The sharpest annual moves came in 2023 and 2025: Operating Expenses slumped 199.19% in 2023, then soared 35.52% in 2025.
• BioLineRx's Operating Expenses stood at -$6.3 million in 2021, then advanced by 20.2% to -$5.0 million in 2022, then decreased by 5.19% to -$5.3 million in 2023, then grew by 28.79% to -$3.8 million in 2024, then advanced by 6.37% to -$3.5 million in 2025.
• Business Quant data shows BLRX's Operating Expenses at -$3.5 million in Q4 2025, -$2.6 million in Q3 2025, and -$2.5 million in Q2 2025.